- US11873304utility2024Fused Pyrimidine Derivatives as A2A/A2B Inhibitors0 cites
- US11873309utility2024Heterocyclic Compounds as Immunomodulators0 cites
- US11866426utility2024Benzothiazole Compounds and Uses Thereof0 cites
- US11866432utility2024Dihydropyrido[2,3-d]pyrimidinone Compounds as CDK2 Inhibitors0 cites
- US11866434utility2024Process for Making a PD-1/PD-L1 Inhibitor and Salts and Crystalline Forms Thereof0 cites
- US11866435utility2024Heterocyclic Compounds as Immunomodulators0 cites
- US11866451utility2024Salts and Crystalline Forms of a PD-1/PD-L1 Inhibitor0 cites
- US11851426utility2023Bicyclic Amines as CDK2 Inhibitors0 cites
- US11840546utility2023Imidazopyridazine Compounds and Uses Thereof0 cites
- US11833152utility2023JAK1 Pathway Inhibitors for the Treatment of Cytokine-related Disorders0 cites
- US11833155utility2023Combination Therapy for Treatment of Myeloproliferative Neoplasms0 cites
- US11795166utility2023Pyrazolopyridine Compounds and Uses Thereof0 cites
- US11787793utility2023Heterocyclic Compounds as Immunomodulators0 cites
- US11787784utility2023Solid Forms of an HPK1 Inhibitor0 cites
- US11780836utility2023Process of Preparing a PD-1/PD-L1 Inhibitor0 cites
- US11780840utility2023Tricyclic Urea Compounds as JAK2 V617F Inhibitors0 cites
- US11773102utility2023Heterocyclic Compounds as Pi3k-γ Inhibitors0 cites
- US11767323utility2023Tricyclic Pyridone Compounds as JAK2 V617F Inhibitors0 cites
- US11767320utility2023Bicyclic Dione Compounds as Inhibitors of KRAS0 cites
- US11760756utility2023Crystalline Form of a PD-1/PD-L1 Inhibitor0 cites